Skip to content
value.today

Compugen Ltd.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 113.3% a year, held within -10% to 25% (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt or cash not on file: 0 to start with.

What today's price assumes

The price's implied growth cannot be worked out with these figures (it needs a positive cash flow, a market value and a discount rate above long-run growth).

Cash-flow value of the shares
$1.0 B
Value of the whole business
$1.0 B
before net debt
Value from after year 10
69%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →20%22.5%25%27.5%30%
8.15%—————
9.15%—————
10.15%—————
11.15%—————
12.15%—————

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Biotechnology: $333 M to $2.1 B, median $708 MPrice to salesPrice to sales of Biotechnology: $163 M to $734 M, median $360 MPrice to bookPrice to book of Biotechnology: $319 M to $1.3 B, median $467 MCash-flow value$0 M$561 M$1.1 B$1.7 B$2.2 B

Your own DCF model

A full discounted-cash-flow model of Compugen Ltd., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Compugen Ltd.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Compugen Ltd.Applied toValue (25th to 75th)Companies
P/E9.4× / 20.0× / 58.8×—net income $35 M$333 M to $2.1 B34
Price to sales2.2× / 5.0× / 10.1×—revenue $73 M$163 M to $734 M85
Price to book3.1× / 4.5× / 12.3×—book equity $103 M$319 M to $1.3 B70

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Compugen Ltd.'s multiples at each month end with a market cap on file, Jan 2020 to Jan 2024, each against its own median.

Price to book

2.2×

Now below its median of 2.6×; range 0.6× to 26.1× over 6 months.

0×7×13×20×26×20202021202220232024Price to book 2×Median 3×

as of Jan 5, 2024. Market caps: the dated values on file since 2020. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Jan 5, 2024.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$73 M$35 M$32 M$0 M$31 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$28 M$-14 M$50 M$0 M$49 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$33 M$-19 M$-36 M$0 M$-36 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$8 M$-34 M$-34 M$0 M$-35 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$6 M$-34 M$-23 M$0 M$-23 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$2 M$-30 M$-28 M$0 M$-28 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value not on file.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.